TITLE

Pharmaceutical Marketing Practices: Pharmaceutical Companies Facing Competition from Generic Drug Manufacturers May Face Increased Scrutiny for Anticompetitive Marketing Practices--In re Warfarin Sodium Antitrust Litig

AUTHOR(S)
Brooks, Karen
PUB. DATE
June 2005
SOURCE
American Journal of Law & Medicine;2005, Vol. 31 Issue 2/3, p382
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports that the U.S. Court of Appeals for the Third Circuit has rejected challenges to a settlement against DuPont Pharmaceuticals Co. concerning marketing practices. End of a class-action consumer antitrust suit over the marketing of the company's widely used blood thinner, Coumadin; Allegation of the plaintiffs that DuPont's anti-competitive behavior and dissemination of false and misleading information about a lower-priced, readily available generic competitor caused them to purchase the higher priced Coumadin instead of the generic product; Emphasis of the case on the risk of pharmaceutical companies facing competition from generic drug manufacturers to face increased scrutiny for anti-competitive marketing practices.
ACCESSION #
17733181

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics